anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The Rice Germ was supplied in vacuum jars of a weight of 130 grams. These jars once opened, were stored in the refrigerator (-3-4°C). Together with cans, small containers were provided to act as dosers and served to determine the correct dose to be taken (25 grams, twice a day). The rice germ or placebo were continually taken every day twice a day (25 grams in the morning with breakfast and 25 grams in the afternoon as snacks) for 5 weeks. The rice germ was supplied by the company "Acquerello" (TenutaColombara, Livorno Ferraris, Vercelli, Italy).
<P>PROBLEM TO BE SOLVED: To provide a scanning suspension comprising a particle having a diameter of at least 1 μm and capable of disturbing a magnetic field at least partly, and the use thereof for obtaining a scanning image.  <P>SOLUTION: Preferably, the particle comprises holmium and a composition capable of essentially maintaining its structure during irradiation. The particle is suitable for preparing a kit of parts, comprising a diagnostic composition and a therapeutic composition, both of which comprise the particles with essentially the same chemical structure, wherein the therapeutic composition is more radioactive than the diagnostic composition. The kit of parts is especially suitable for treatment of tumor. Firstly, the distribution of the particles within an individual can be determined with a scanning image obtained with a scanning composition. Subsequently, a radioactive therapeutic composition can be administered, wherein a suitable dose of the therapeutic composition is derived from the scanning image.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Lonafarnib starting at 50 mg BID in combination with ritonavir 100 mg BID and escalating to lonafarnib 75 mg BID and then 100 mg BID as tolerated. The duration of the study for each patient is 6 months of treatment and 6 months follow-up.
THIS IS THE SECOND PART OF A 2-PART STUDY. Part 1 of the study will be a single center study intended to assess the safety and tolerability of valproic acid dosages at 15 mg/kg, 30 mg/kg, 60 mg/kg, 90 mg/kg, 120 mg/kg, 150 mg/kg 180 mg/kg, 210 mg/kg and 250 mg/kg. Up to 72 healthy subjects (9 dose groups of 8 subjects) will receive single doses of valproic acid or placebo via a 60-min IV infusion in a ratio of 3:1 active drug: placebo. ID: VPA-C-002

Part 2 of the study will be a multi-center, double blind, placebo-controlled study in trauma patients with hemorrhagic shock. The patients will be able to consent themselves, or if unable due to injuries, a Legally Authorized Representative will consent for them. Up to 12 patients (2 dose groups of 6 patients) will receive single doses of valproic acid or placebo via a 60-min IV infusion in a ratio of 2:1 active drug : placebo. The dose levels in Part 2 will be the two highest doses that are demonstrated to have acceptable safety profile based on the review of safety data from Part 1 (130mg/kg and 140mg/kg).
This is a multicenter study of COVID-19 vaccine immunogenicity and durability, and breakthrough serious acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections in people who receive a COVID-19 vaccine through their country's national vaccination programs. Participants will be enrolled upon signing the informed consent within a day of receipt of a COVID-19 vaccine (before or after). The study team will not be administering the vaccine; receipt of vaccine will be provided through each country's vaccine program. Blood specimens will be collected to measure the immune response to the vaccine. Participants may be asked to contact study staff at any time during the study for evaluation if they develop symptoms consistent with SARS-CoV-2 infection, at which time they will be counseled about the need for a medical evaluation that may include collection of an upper airway swab for diagnosis (and research) and a blood sample for research. Infections will be confirmed by molecular or antigen (Ag) testing at the time of symptoms, and swabs will be collected and stored for viral sequencing and analyses.
This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
Infectious diseases, driven by a diverse array of pathogens, can swiftly undermine public health systems. Accurate diagnosis and treatment of infectious diseases-centered around the identification of biomarkers and the elucidation of disease mechanisms-are in dire need of more versatile and practical analytical approaches. Mass spectrometry (MS)-based molecular profiling methods can deliver a wealth of information on a range of functional molecules, including nucleic acids, proteins, and metabolites. While MS-driven omics analyses can yield vast datasets, the sheer complexity and multi-dimensionality of MS data can significantly hinder the identification and characterization of functional molecules within specific biological processes and events. Artificial intelligence (AI) emerges as a potent complementary tool that can substantially enhance the processing and interpretation of MS data. AI applications in this context lead to the reduction of spurious signals, the improvement of precision, the creation of standardized analytical frameworks, and the increase of data integration efficiency. This critical review emphasizes the pivotal roles of MS based omics strategies in the discovery of biomarkers and the clarification of infectious diseases. Additionally, the review underscores the transformative ability of AI techniques to enhance the utility of MS-based molecular profiling in the field of infectious diseases by refining the quality and practicality of data produced from omics analyses. In conclusion, we advocate for a forward-looking strategy that integrates AI with MS-based molecular profiling. This integration aims to transform the analytical landscape and the performance of biological molecule characterization, potentially down to the single-cell level. Such advancements are anticipated to propel the development of AI-driven predictive models, thus improving the monitoring of diagnostics and therapeutic discovery for the ongoing challenge related to infectious diseases.
The present disclosure provides a composition for enhancing effect of an inhibitor in inhibiting NAD + /NADP +  or NADH/NADPH dependent enzymes. The inhibition of the NAD + /NADP +  or NADH/NADPH dependent enzymes such as Enoyl-ACP reductase (ENR) by the composition of the present disclosure serves as a target for treating malaria and other infectious diseases. The present disclosure provides composition comprising inhibitor and polyphenol, wherein the polyphenol was found to enhance the inhibitory activity of the inhibitor. The present disclosure provides method for treating an infectious disease comprising administering an effective amount of the composition of the present disclosure to patients in need thereof. The present disclosure further provides a method for identifying a compound that enhances the effect of the inhibitor, a method of determining the antimalarial activity of a compound and use of polyphenol as a bioenhancer that enhances effect of an inhibitor for inhibiting NAD + /NADP +  or NADH/NADPH dependent enzymes. The present disclosure provides a composition comprising inhibitor and a polyphenol wherein the polyphenol enhances effect of the inhibitor for inhibiting aldose reductase for treating complications of diabetes that include diabetic retinopathy, cataract neuropathy and neural complication.
Congenital aniridia is a rare and severe genetic panocular disease characterized by a complete or partial iris defect clinically detectable at birth. The most common form of aniridia occurring in around 90% cases is caused by PAX6 haploinsufficiency. Ataluren eye-drops aim to restore ocular surface PAX6 haploinsufficiency in Aniridia Related Keratopathy (ARK). However, they are currently no ophthalmic solution available forms. The objective of this study was to assess the physicochemical and microbiological stability of ataluren eye-drop 1% in preservative-free low-density polyethylene (LDPE) bottle with an innovative insert that maintains sterility after opening. Because ataluren is a strongly lipophilic compound, the formulation is complex and involves a strategy based on co-solvents in an aqueous phase or an oily formulation capable of totally dissolving the active ingredient. Throughout the 60 days period, the new formulation of the solution in LDPE bottle remained clear without any precipitation or color modification, no drug loss and no microbial development were detected. Thus, the present invention refers to a pharmaceutical solution comprising: ataluren or any one of its pharmaceutically acceptable derivatives, at least one solvent selected from the group consisting in dimethylsulfoxyde (DMSO), polyethylene glycol, polysorbate, glycerol, tyloxapol, and poloxamer, and castor oil; and its use for treating aniridia.
The invention relates to an oral liquid for controlling hyperpyrexia, and the oral liquid is a latest product mainly treating hyperpyrexia at present. Hyperpyrexia, i.e. high fever, refers to a symptom that a body temperature exceeds the normal level and can be caused by a plurality of diseases. In traditional Chinese medicine, hyperpyrexia is divided into exogenous fever and interior fever. The product is prepared by 6 Chinese herbal medicines: folium isatidis, isatis roots, clematis roots, radix angelicae pubescentis, incised notopterygium rhizome, and platycodon grandiflorum. The oral liquid of the invention can clear heat and remove toxicity, expel clod, and relieve exterior symptoms by dispelling wind. Patients with exogenous fever can reach a substantial treatment effect by taking the oral liquid provided in the invention.
The patent name: a pure natural health tea for enlarging and lifting breasts of adult females is provided. The technical field is as follows: belongs to the field of biological preparation. The problems are solved: helps solve the problem that the breasts of the adult women are too small (commonly called 'small chest'). The technical scheme is as follows: the tea drink is prepared by the method described in the patent specification. After being taken orally, the medicine can dredge the channels and collaterals connecting the breasts, and simultaneously generate and deliver the necessary nutrients for the regrowth of the breasts, so that the regrowth of the breasts is enlarged. The main application is as follows: enlarging and lifting the chest.
The heat shock response (HSR) is a crucial biochemical pathway that orchestrates the resolution of inflammation, primarily under proteotoxic stress conditions. This process hinges on the upregulation of heat shock proteins (HSPs) and other chaperones, notably the 70 kDa family of heat shock proteins, under the command of the heat shock transcription factor-1. However, in the context of chronic degenerative disorders characterized by persistent low-grade inflammation (such as insulin resistance, obesity, type 2 diabetes, nonalcoholic fatty liver disease, and cardiovascular diseases) a gradual suppression of the HSR does occur. This work delves into the mechanisms behind this phenomenon. It explores how the Western diet and sedentary lifestyle, culminating in the endoplasmic reticulum stress within adipose tissue cells, trigger a cascade of events. This cascade includes the unfolded protein response and activation of the NOD-like receptor pyrin domain-containing protein-3 inflammasome, leading to the emergence of the senescence-associated secretory phenotype and the propagation of inflammation throughout the body. Notably, the activation of the NOD-like receptor pyrin domain-containing protein-3 inflammasome not only fuels inflammation but also sabotages the HSR by degrading human antigen R, a crucial mRNA-binding protein responsible for maintaining heat shock transcription factor-1 mRNA expression and stability on heat shock gene promoters. This paper underscores the imperative need to comprehend how chronic inflammation stifles the HSR and the clinical significance of evaluating the HSR using cost-effective and accessible tools. Such understanding is pivotal in the development of innovative strategies aimed at the prevention and treatment of these chronic inflammatory ailments, which continue to take a heavy toll on global health and well-being.
PROBLEM TO BE SOLVED: To obtain a dental cement composition used in a non aqueous system, increasing the initial curing speed, and excellent in physical characteristics and endurance of a cured material by utilizing a polymerizable monomer as a reactive solvent in addition to a specific polymer containing carboxyl group with a specific metallic cross-linking agent. SOLUTION: This dental cement composition consists of a polymer or a copolymer using an α,β-unsaturated carboxylic acid as a monomer with an inorganic powdery material capable of forming a metal chelate in the presence of water, and the polymer or the copolymer is dissolved with a polymerizable monomer capable of dissolving them. Further, the above inorganic powdery material is preferably dispersed in the solution. As the α,β-unsaturated carboxylic acid, (meth)acrylic acid is preferred, and as the polymerizable monomer, an alkyl(meth)acrylate having hydroxyl group in molecule thereof, is preferred. The weight averaged molecular weight of the above polymer or copolymer is preferably 2,000-50,000.  As the inorganic powdery material, a compound selected from an oxide, a hydroxide, a carbonic acid salt, a phosphoric acid salt and a silicic acid salt of a poly-valent metal, is preferable.
Joint hyper-resistance is a common symptom in neurological disorders. It has both neural and non-neural origins, but it has been challenging to distinguish different origins based on clinical tests alone. Combining instrumented tests with parameter identification based on a neuromechanical model may allow us to dissociate the different origins of joint hyper-resistance in individual patients. However, this requires that the model captures the underlying mechanisms. Here, we propose a neuromechanical model that, in contrast to previously proposed models, accounts for muscle short-range stiffness (SRS) and its interaction with muscle tone and reflex activity. We collected knee angle trajectories during the pendulum test in 15 children with cerebral palsy (CP) and 5 typically developing children. We did the test in two conditions - hold and pre-movement - that have been shown to alter knee movement. We modeled the lower leg as an inverted pendulum actuated by two antagonistic Hill-type muscles extended with SRS. Reflex activity was modeled as delayed, linear feedback from muscle force. We estimated neural and non-neural parameters by optimizing the fit between simulated and measured knee angle trajectories during the hold condition. The model could fit a wide range of knee angle trajectories in the hold condition. The model with personalized parameters predicted the effect of pre-movement demonstrating that the model captured the underlying mechanism and subject-specific deficits. Our model may help with the identification of neural and non-neural origins of joint hyper-resistance and thereby opens perspectives for improved diagnosis and treatment selection in children with spastic CP, but such applications require further studies to establish the method's reliability.
Participants received ASP8374 0.5 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
OBJECTIVES: This study aimed to investigate the impact of bowel dysfunction and lower urinary tract symptoms on the quality of patients with rectal cancer who underwent sphincter-preserving surgery.
METHODS: This cross-sectional study included patients who were followed up after sphincter-preserving surgery in Korea. Data were collected from May 2022 to February 2023. The participants (n = 110) responded to self-reported questionnaires assessing the Low Anterior Resection Syndrome (LARS) score, International Prostate Symptom Score (IPSS), European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-C29 questionnaires.
RESULTS: Among the participants, 66.4% had major low anterior resection syndrome, and 39.1% had moderate-to-severe lower urinary tract symptoms. Patients with higher severity of low anterior resection syndrome and lower urinary tract symptoms had a lower quality of life. The IPSS, performance status, duration since the end of the surgery, comorbidities, LARS scores, and tumor location on the anal verge negatively affected the quality of life.
CONCLUSION: Patients with more severe bowel dysfunction or lower urinary tract symptoms have a poorer quality of life. Nurses should be made aware of the factors that can reduce the quality of life of patients who have undergone sphincter-preserving surgery. Accordingly, they should plan to address the various nursing problems.
Following ethics committee approval, 20 patients with uncontrolled glaucoma will be will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with Mitomycin-C.
BACKGROUND: Urologic emergencies are common and complications from their management are high. Simulation-based education (SBE) is a highly effective training method, allowing trainees to learn both technical and nontechnical skills in a safe environment. Training in the management of urological emergencies is limited in many healthcare settings, so we performed a needs assessment for a urological emergencies SBE course in Ethiopia.
METHODS: This study presents data from a descriptive cross-sectional, survey-based survey of consultants and residents in the Ethiopian surgical community. The survey was disseminated using online Google Forms, through social media (WhatsApp), and to colleagues in the College of Surgeons of East, Central and Southern Africa (COSECSA) via email and social media.
RESULTS: One hundred-seven results were received; two were discarded due to incomplete data. Fifty three of the respondents were general surgeons and 38 of the respondents were urologists. Sixty nine respondents strongly agreed that simulation-based training was important for first-year surgical residents, whereas twenty-five respondents agreed and nine respondents strongly disagreed; one respondent disagreed and one was neutral. Eighty seven respondents suggested a 3-day training course, whereas 17 respondents suggested a two-day course. More than 80 of the respondents rated training in the management of acute urinary retention, acute scrotum, urethral, and suprapubic catheterization as extreme or very important and 79 respondents wanted education about urologic trauma and Fournier's gangrene.
CONCLUSION: Surgical and urology residents in Ethiopia have expressed a need for, and a strong interest in, simulation-based urological emergency training.
PURPOSE: A composition containing Matteuccia orientalis extract is provided to reduce osteoclast formation and to suppress bond absorption. CONSTITUTION: A pharmaceutical composition for preventing and treating bone diseases contains Matteuccia orientalis extract as an active ingredient. The bone diseases are caused by metastasis. The extract suppresses osteoclast formation and bone resorption. The bone diseases are osteoporosis. A food composition for treating and relieving bone diseases contains the extract as an active ingredient.
The invention relates to a xinnaojian preparation, which has the function of dispelling wind-heat, improving mentality and vision, promoting resuscitation, strengthening brain, dissolving turbidity and reducing lipid, belonging to medicine domain. The xinnaojian preparations are mainly prepared by tea extract and proper adjuvant. The preparations mainly refer to chewable tablet and buccal tablet. The adjuvant kind, dosage and the ratio of of the main components are reasonable. The process is reasonable and feasible. The quality is stable and is well controlled. The volume of the preparation is compact. The preparation can be directly admitted after dissolving in mouth or by chawing. The flavour is tasty, so that the  preparation especially fits for wean, elder and the patient of dysphagia. The storage and transportation are very convenient.
Patients will be initiated on bexarotene 150 mg daily on Day 1, with dose increase to 300 mg daily on Day 15. Patients will receive Cycle 1 of TSEB on Day 22 (with 2 Gy given on two consecutive days -Day 22 and 23), with safety assessment on Day 52. Efficacy will first be assessed on Day 52 and then again on Day 82 by global response assessment, including mSWAT. Patients who have less than 70% reduction from baseline mSWAT score will be eligible for subsequent cycles of TSEB (administered as 4 Gy over 2 consecutive days), until mSWAT score reduction of ≥ 70%, and up to a total of 6 cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by treating physician, or termination of the study.
PURPOSE: To obtain a cosmetic excellent in use feeling and stability by formulating insolubilized collagen beads in an emulsion-based cosmetic such as suspended cosmetic, cream or milky lotion. CONSTITUTION: Firstly, collagen or a derivative therefrom is prepared into collagen beads which are then insolubilized by a crosslinking agent, ultraviolet light or γ-ray irradiation, etc. The resultant collagen beads are then formulated at 0.1-40 (pref. 1.0-30)wt.% in an emulsion-based cosmetic stock such as suspended face lotion, cream or milky lotion to obtain the objective cosmetic. This cosmetic, because of high thermal stability of the collagen, is improved in use feeling. Especially, the particle diameter of the collagen beads is regulated to 0.1-50μm. In addition, water or an active ingredient is included in the beads, being sustainedly released, resulting in a stable, equilibrium state eventually.
Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex is to be given.
A treatment for cancer with the use of an antibody binding to mortalin 2 and a functional nucleic acid. Mortalin shows upregulated expression in immortalized cells or tumor tissues. Immortalized human cells with overexpression of mortalin show scaffold-independent proliferation. By injecting K antibody that is a specific anti-mortalin antibody into a tumor of a nude mouse, the tumor growth is regulated or the tumor size is reduced compared with a control. Namely, it is intended to provide the utilization of a specific anti-mortalin antibody (K antibody) in treating tumor and utilization thereof as a carrier molecule for transporting an immunotoxin or the like into cells. It is indicated that mortalin serves as a target in treating cancer. Thus, a novel and efficacious anticancer agent is provided. Moreover, an anti-mortalin antibody internalized in cells is developed and various methods of using the same are provided.
The parents/guardians this study arm will use the Beanstack mobile app (or the Bookroo app, as an alternative) focused on parents reading to their children for the first 8 weeks of the study. This app may help parents/guardians to read more to their preschool children (and other children), which is good for child learning and development.
Participants will undertake approximately 30 minutes of computerized CRT training for 8 weeks, 5 days per week. They will meet a therapist once per week to discuss any difficulties, help motivation.